Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.60 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | CDK1 | P06493 | 3/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 9/20 | 0.51 |
| ▸ | JAK3 | P52333 | 7/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CCNH | P51946 | 2/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048139 | 0.91 | FLT3 (0.63) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL4555951 | 0.90 | FLT3 (0.65) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3043711 | 0.89 | FLT3 (0.62) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3046183 | 0.89 | FLT3 (0.76) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3039375 | 0.88 | FLT3 (0.56) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3162405 | 0.86 | FLT3 (0.60) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3040112 | 0.85 | FLT3 (0.62) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3036401 | 0.85 | FLT3 (0.60) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3035596 | 0.84 | FLT3 (0.56) | FLT3CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL3041623 | 0.84 | FLT3 (0.58) | FLT3CDK2CDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | claimed |
| EP-2040546-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | claimed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2040546-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007149427-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | FLT3 11/4885CDK2 145/4885CDK1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.